Patients with a type of cancer known as primary mediastinal B-cell lymphoma who received infusions of chemotherapy, but who did not have radiation therapy to an area of the thorax known as the mediastinum, had excellent outcomes, according to clinical trial results. The results of this single arm trial, which followed 51 patients for a period of up to 14 years, was conducted by researchers at the National Cancer Institute, part of the National Institutes of Health, and appeared in The New England Journal of Medicine. Read more here.
Study mentioned: Dunleavy K, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013 Apr 11;368(15):1408-16. PMID: 23574119
No comments:
Post a Comment